Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.

ABSTRACT:

Background

Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the use of donor-generated allogeneic CAR T is paving the way for further breakthroughs in the treatment of cancer. However, it remains unknown how the intrinsic heterogeneities of these engineered cells mediate therapeutic efficacy and whether allogeneic products match the effectiveness of autologous therapies.

Methods

Using single-cell mRNA sequencing in conjunction with CITE-seq, we performed multiomics characterization of CAR T cells generated from healthy donor and patients with acute lymphoblastic leukemia. CAR T cells used in this study were manufactured

SUBMITTER: Bai Z 

PROVIDER: S-EPMC8137188 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature